Program Overview
Acute
hepatic porphyria (AHP) is a group of rare inherited diseases with variable,
non-specific, and dynamic symptoms and associated with an average diagnostic
delay of 15 years. During that time, patients experience hallucinations,
dreadful pain, seizures, and frequent hospitalizations. This activity will
educate gastroenterologists and other healthcare providers on the hallmark
signs of AHP, strategies for differential diagnosis, and current management
options for improving patient outcomes.
Target Audience
This
initiative is intended for gastroenterologists, physicians, nurses, physician
assistants and other healthcare professionals assessing patients in the
gastroenterology setting.
Educational Objectives
Upon completion of this activity, the learner should be able to:
AGENDA
- Introduction
- Recognizing Signs and Symptoms of AHP in Patients
- Strategies for Screening AHP and Reaching a Differential Diagnosis
- Improving AHP Patient Care: Focusing on Disease-Specific Therapy
- Q&A
Karl E. Anderson, MD, FACP
Professor, Departments of Internal Medicine (Division of Gastroenterology and Hepatology) and Preventive Medicine and Population Health
Director, Clinical Science Graduate Program
Director, Porphyria Laboratory and Center
Member, Institute for Translational Sciences
University of Texas Medical Branch/UTMB Health
Galveston, TX
D. Montgomery Bissell, MD
Professor of Medicine, Emeritus
Department of Medicine
Director Emeritus, UCSF Liver Center
San Francisco, CA
Herbert Lloyd Bonkovsky, MD
Professor of Medicine and Molecular Medicine and Translational Research and Director of the Liver and Metabolic Disorders Laboratory
Wake Forest University School of Medicine
Winston Salem, NC
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
CRITERIA FOR SUCCESS
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
Nurses
1.5 ANCC contact hours
Provider Information
This program is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC
Commercial Support:
This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)